TipRanks
BioNTech SE (CH:22UA)
:22UA
Switzerland Market
22UA
BioNTech SE
RESEARCH TOOLSreports

BioNTech SE (22UA) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

22UA Analyst Ratings

Strong Buy
14Ratings
Strong Buy
11 Buy
3 Hold
0 Sell
Based on 14 analysts giving stock ratings to
BioNTech
SE
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

22UA Stock 12 Month Forecast

Average Price Target

CHF105.19
▲(26.69% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is CHF105.19 with a high forecast of CHF116.10 and a low forecast of CHF79.61. The average price target represents a 26.69% change from the last price of CHF83.03.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"69":"CHF69","81":"CHF81","93":"CHF93","105":"CHF105","117":"CHF117"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":116.0984608,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF116.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.19030871384615,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF105.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.61037312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF79.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[69,81,93,105,117],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.332,85.85249698461539,88.37299396923076,90.89349095384615,93.41398793846153,95.93448492307692,98.4549819076923,100.97547889230769,103.49597587692307,106.01647286153846,108.53696984615384,111.05746683076923,113.5779638153846,{"y":116.0984608,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.332,85.01340836260354,86.69481672520709,88.37622508781064,90.0576334504142,91.73904181301775,93.4204501756213,95.10185853822485,96.7832669008284,98.46467526343194,100.1460836260355,101.82749198863905,103.5089003512426,{"y":105.19030871384615,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,83.332,83.04572100923076,82.75944201846153,82.47316302769231,82.18688403692308,81.90060504615384,81.61432605538461,81.32804706461539,81.04176807384616,80.75548908307692,80.46921009230769,80.18293110153847,79.89665211076924,{"y":79.61037312,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":70.855,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.316,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.595,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.332,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF116.10Average Price TargetCHF105.19Lowest Price TargetCHF79.61
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:22UA
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF95.37
Buy
14.86%
Upside
Assigned
09/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), BioNTech SE (NASDAQ: BNTX) and AgomAb Therapeutics NV ADR (NASDAQ: AGMB)
Bernstein Analyst forecast on CH:22UA
Jeffrey Walch
Bernstein
Bernstein
CHF79.61
Hold
-4.12%
Downside
Reiterated
09/25/26
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (NASDAQ: HRMY), BioNTech SE (NASDAQ: BNTX) and Biogen (NASDAQ: BIIB)
Wells Fargo Analyst forecast on CH:22UA
Mohit Bansal
Wells Fargo
Wells Fargo
CHF116.1
Buy
39.83%
Upside
Reiterated
09/24/26
Wells Fargo Remains a Buy on BioNTech SE (BNTX)
Canaccord Genuity Analyst forecast on CH:22UA
John Newman
Canaccord Genuity
Canaccord Genuity
CHF112.78
Buy
35.83%
Upside
Reiterated
09/23/26
Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX)
UBS Analyst forecast on CH:22UA
David Dai
UBS
UBS
CHF111.95
Buy
34.83%
Upside
Reiterated
09/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on CH:22UA
Akash Tewari
Jefferies
Jefferies
CHF114.44
Buy
37.83%
Upside
Reiterated
09/15/26
Jefferies Remains a Buy on BioNTech SE (BNTX)
Berenberg Bank Analyst forecast on CH:22UA
Harry Gillis
Berenberg Bank
Berenberg Bank
CHF109.46→CHF116.1
Buy
39.83%
Upside
Reiterated
09/15/26
Berenberg Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Goldman Sachs Analyst forecast on CH:22UA
Asad Haider
Goldman Sachs
Goldman Sachs
CHF105.32
Buy
26.84%
Upside
Reiterated
09/14/26
BioNTech: Buy Rating Reiterated on Strengthening Oncology Pipeline and De-Risked Programs; Price Target Unchanged at $127
BMO Capital Analyst forecast on CH:22UA
Evan Seigerman
BMO Capital
BMO Capital
CHF87.07
Hold
4.87%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and BioNTech SE (NASDAQ: BNTX)
Bank of America Securities Analyst forecast on CH:22UA
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF101.17
Buy
21.85%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (NASDAQ: BNTC), CVS Health (NYSE: CVS) and BioNTech SE (NASDAQ: BNTX)
Citi Analyst forecast on CH:22UA
Geoff Meacham
Citi
Citi
CHF103.66
Buy
24.85%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), BioNTech SE (BNTX)
Deutsche Bank Analyst forecast on CH:22UA
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
CHF116.1
Buy
39.83%
Upside
Reiterated
08/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on CH:22UA
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
08/19/26
BioNTech: Cash-Rich Oncology Pipeline Supports Sentiment, But Clinical and Valuation Uncertainties Warrant Hold Rating
Evercore ISI Analyst forecast on CH:22UA
Cory Kasimov
Evercore ISI
Evercore ISI
CHF111.95→CHF107.81
Buy
29.84%
Upside
Reiterated
08/05/26
BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI
TD Cowen Analyst forecast on CH:22UA
Yaron Werber
TD Cowen
TD Cowen
CHF77.95
Hold
-6.12%
Downside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:22UA
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF95.37
Buy
14.86%
Upside
Assigned
09/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), BioNTech SE (NASDAQ: BNTX) and AgomAb Therapeutics NV ADR (NASDAQ: AGMB)
Bernstein Analyst forecast on CH:22UA
Jeffrey Walch
Bernstein
Bernstein
CHF79.61
Hold
-4.12%
Downside
Reiterated
09/25/26
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (NASDAQ: HRMY), BioNTech SE (NASDAQ: BNTX) and Biogen (NASDAQ: BIIB)
Wells Fargo Analyst forecast on CH:22UA
Mohit Bansal
Wells Fargo
Wells Fargo
CHF116.1
Buy
39.83%
Upside
Reiterated
09/24/26
Wells Fargo Remains a Buy on BioNTech SE (BNTX)
Canaccord Genuity Analyst forecast on CH:22UA
John Newman
Canaccord Genuity
Canaccord Genuity
CHF112.78
Buy
35.83%
Upside
Reiterated
09/23/26
Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX)
UBS Analyst forecast on CH:22UA
David Dai
UBS
UBS
CHF111.95
Buy
34.83%
Upside
Reiterated
09/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on CH:22UA
Akash Tewari
Jefferies
Jefferies
CHF114.44
Buy
37.83%
Upside
Reiterated
09/15/26
Jefferies Remains a Buy on BioNTech SE (BNTX)
Berenberg Bank Analyst forecast on CH:22UA
Harry Gillis
Berenberg Bank
Berenberg Bank
CHF109.46→CHF116.1
Buy
39.83%
Upside
Reiterated
09/15/26
Berenberg Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Goldman Sachs Analyst forecast on CH:22UA
Asad Haider
Goldman Sachs
Goldman Sachs
CHF105.32
Buy
26.84%
Upside
Reiterated
09/14/26
BioNTech: Buy Rating Reiterated on Strengthening Oncology Pipeline and De-Risked Programs; Price Target Unchanged at $127
BMO Capital Analyst forecast on CH:22UA
Evan Seigerman
BMO Capital
BMO Capital
CHF87.07
Hold
4.87%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and BioNTech SE (NASDAQ: BNTX)
Bank of America Securities Analyst forecast on CH:22UA
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF101.17
Buy
21.85%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (NASDAQ: BNTC), CVS Health (NYSE: CVS) and BioNTech SE (NASDAQ: BNTX)
Citi Analyst forecast on CH:22UA
Geoff Meacham
Citi
Citi
CHF103.66
Buy
24.85%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), BioNTech SE (BNTX)
Deutsche Bank Analyst forecast on CH:22UA
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
CHF116.1
Buy
39.83%
Upside
Reiterated
08/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on CH:22UA
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
08/19/26
BioNTech: Cash-Rich Oncology Pipeline Supports Sentiment, But Clinical and Valuation Uncertainties Warrant Hold Rating
Evercore ISI Analyst forecast on CH:22UA
Cory Kasimov
Evercore ISI
Evercore ISI
CHF111.95→CHF107.81
Buy
29.84%
Upside
Reiterated
08/05/26
BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI
TD Cowen Analyst forecast on CH:22UA
Yaron Werber
TD Cowen
TD Cowen
CHF77.95
Hold
-6.12%
Downside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTVTvTv Therapeutics
MDWDMediwound
AXGNAxoGen
SIBNSI-Bone
LGNDLigand Pharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

3 Months
John NewmanCanaccord Genuity
Success Rate
11/15 ratings generated profit
73%
Average Return
+6.00%
Copying John Newman's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +6.00% per trade.
1 Year
John NewmanCanaccord Genuity
Success Rate
9/15 ratings generated profit
60%
Average Return
>-0.01%
Copying John Newman's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of >-0.01% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
12/22 ratings generated profit
55%
Average Return
+0.73%
Copying Robert Burns's trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +0.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

22UA Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
14
9
8
6
4
Buy
19
12
10
21
33
Hold
5
6
5
5
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
38
27
23
32
43
In the current month, 22UA has received 37 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 22UA average Analyst price target in the past 3 months is 105.19.
Each month's total comprises the sum of three months' worth of ratings.

22UA Financial Forecast

22UA Earnings Forecast

Next quarter’s earnings estimate for 22UA is CHF0.69 with a range of -CHF0.02 to CHF1.28. The previous quarter’s EPS was -CHF3.04. 22UA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 22UA is CHF0.69 with a range of -CHF0.02 to CHF1.28. The previous quarter’s EPS was -CHF3.04. 22UA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.

22UA Sales Forecast

Next quarter’s sales forecast for 22UA is CHF990.89M with a range of CHF796.70M to CHF1.13B. The previous quarter’s sales results were CHF101.33M. 22UA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.
Next quarter’s sales forecast for 22UA is CHF990.89M with a range of CHF796.70M to CHF1.13B. The previous quarter’s sales results were CHF101.33M. 22UA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.

22UA Stock Forecast FAQ

What is CH:22UA’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is 105.19.
    What is CH:22UA’s upside potential, based on the analysts’ average price target?
    BioNTech SE has 26.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioNTech SE a Buy, Sell or Hold?
          BioNTech SE has a consensus rating of Strong Buy, which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.
            What is BioNTech SE’s share price target?
            The average share price target for BioNTech SE is 105.19. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF116.10 ,and the lowest forecast is CHF79.61. The average share price target represents 26.69% Increase from the current price of CHF83.03.
              What do analysts say about BioNTech SE?
              BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of BioNTech SE?
                To buy shares of CH:22UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.